<DOC>
	<DOCNO>NCT02258464</DOCNO>
	<brief_summary>The objective study assess efficacy safety radium-223 dichloride subject human epidermal growth factor receptor 2 negative ( HER2 negative ) hormone receptor positive breast cancer bone metastasis treat hormonal treatment background therapy .</brief_summary>
	<brief_title>Study Radium-223 Dichloride Versus Placebo Hormonal Treatment Background Therapy Subjects With Bone Predominant HER2 ( Human Epidermal Growth Factor Receptor 2 ) Negative Hormone Receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Documentation histological cytological confirmation estrogen receptor positive ( ER+ ) HER2 negative adenocarcinoma breast must available . Women ( â‰¥18 year age ) metastatic breast cancer amenable curative treatment surgery radiotherapy . Documentation menopausal status : post menopausal premenopausal subject eligible . Subjects bone dominant disease least 2 skeletal metastasis identify baseline bone scintigraphy confirm CT/magnetic resonance imaging ( MRI ) . Presence metastases soft tissue ( skin , subcutaneous , muscle , fat , lymph node ) and/or visceral metastasis allow . Measurable nonmeasurable disease ( radiologically evaluable ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 criterion . Subjects must receive least one line hormonal therapy metastatic setting Subjects eligible standard care endocrine treatment . Subjects enrol current study must start treatment single hormone agent either within 15 day prior randomization randomization ( simultaneously first injection Ra223/placebo ) . Subjects must experience two skeletalrelated event ( SREs ) prior study entry define : Need external beam radiotherapy ( EBRT ) tor bone , pathological bone fracture ( exclude major trauma ) , spinal cord compression and/or orthopedic surgical procedure . Subjects prior SREs permit . Subjects must therapy bisphosphonate denosumab . require therapy least 1 month start study treatment . Adequate hematological , liver kidney function . Subjects Inflammatory breast cancer . Subjects either received chemotherapy metastatic disease consider treat investigator appropriate candidate chemotherapy current treatment metastatic breast cancer exclude . Chemotherapy administer adjuvant/neo adjuvant disease acceptable . Subjects know history brain metastasis leptomeningeal disease : subject neurological symptom must undergo contrast CT scan MRI brain within 28 day prior randomization exclude active brain metastasis . Imaging central nervous system ( CNS ) otherwise require . Known presence osteonecrosis jaw . Patients immediately lifethreatening visceral disease , chemotherapy prefer treatment option . Lymphangitic carcinomatosis . Patients ascites require paracentesis within 2 week prior study entry ( signature inform consent ) screening period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>